UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN) [1206P]
(2021) ESMO Congress 2021 — Location: Virtual Annual Meeting (16.September.2021)
Files
2021_Bar_Ann_Oncol.pdf
Open Access - Adobe PDF
- 124.02 KB
Details
- Authors
- Abstract
- BACKGROUND : About 10% of EGFR mutations (EGFRmut) are ‘uncommon mutations’ (ucEGFRmut), correlating with lower response to 1st & 2nd generation EGFR inhibitors (EGFRi) compared to common mutations. Osimertinib is a 3rd generation EGFRi, active against common EGFRmut. Efficacy data of osimertinib in ucEGFRmut are scarce. We aimed to collect real-world data of the usage of osimertinib as the 1st EGFRi for ucEGFRmut. [...]
- Affiliations
Citations
Bar, J., Kian, W., Wolner, M., Derijcke, S., Girard, N., Rottenberg, Y., Dudnik, E., Metro, G., Hochmair, M. J., Aboubakar Nana, F., Cuppens, K., Decoster, L., Reck, M., Limon, D., Blanco, A. C., Astaras, C., Häfliger, S., Peled, N., & Addeo, A. (2021). UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN) [1206P]. Annals of Oncology, 32(Suppl 5), S961-S962. https://doi.org/10.1016/j.annonc.2021.08.1811 (Original work published 2021)